The Mount Sinai Robotics Institute will focus on treatment of urological disease, oral and throat cancers, obstetrical conditions, cardiovascular disease and neurological conditions. An international leader in robotic and minimally invasive surgery, MSRI will research techniques and refinements and complication reduction programs.
Eric Genden, MD, the Dr. Isidore Friesner professor and chair of the department of otolaryngology-head and neck surgery at Mount Sinai and MSRI co-chair, said Mount Sinai was “an early adopter of the da Vinci Surgical System and we have been studying robotic oropharyngeal cancer treatment since then. We have found robotic surgery — for a variety of disease conditions — minimizes our patients’ recovery time and maximizes their outcomes.”
Robotic surgeries in head and neck patients at Mount Sinai include rapid turnaround of tumor results from pathology at the time of surgery, allowing for more accurate resection; precision medicine like NeuroSAFE, which lets a surgeon know if all of the cancer has been excised during operation; and reconstruction techniques to minimize nerve damage during prostate cancer surgery.
Mount Sinai preformed its first minimally invasive robotic surgery to treat head and neck cancer in 2008.
More articles on integration and physician issues:
How ACOs, healthcare could change under the Trump administration
How technology-driven solutions can improve OR efficiencies
Surgeon who launched kidney transplant program in St. Louis hospitals dies at 78
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
